On April 6, 2026, MISTR — the largest US telehealth platform for HIV prevention and treatment — announced it would provide free, long-term HIV care plus up to $250/month in insurance premium support to any Florida resident affected by the state's recent AIDS Drug Assistance Program (ADAP) changes. The move turns a state-level Medicaid policy gap into a direct customer-acquisition channel for one of the few profitable, vertically integrated companies in HIV care.

Why It Matters

HIV care is one of the few sexual-health verticals where adherence determines public-health outcomes for the entire population, not just the patient. Treatment interruptions translate measurably into community viral load, new infections, and downstream PrEP demand. MISTR stepping into Florida's ADAP gap is both a competitive customer-acquisition move and a real-world proof point that direct-to-consumer telehealth can substitute for state-administered safety-net programs in HIV — a precedent that will be tested in the courts, in CMS rulemaking, and in state legislatures as more red-state ADAP programs come under fiscal pressure. For Merck's IDVYNSO, which launched commercially May 11, 2026 (covered separately), MISTR is also positioned to be one of the first telehealth platforms to switch eligible patients onto the new regimen at scale.

The trigger is Florida's 2026 ADAP eligibility tightening, which has left an estimated several thousand Floridians with HIV either losing premium subsidies or facing extended re-enrollment friction. ADAP funds — federal Ryan White Part B dollars administered by the state — historically covered insurance premiums for low-income people living with HIV, allowing them to stay on private-plan formularies that include high-cost antiretrovirals like Biktarvy. With those subsidies disrupted, patients face a gap that can quickly translate into treatment interruptions, viral rebound, and increased onward transmission. MISTR's announcement effectively offers to absorb the gap for affected residents on its platform.

The mechanics: every six months, MISTR patients complete a short questionnaire and a video consult with a licensed HIV specialist, then have lab work coordinated at one of 2,200+ partner locations nationwide. MISTR's "Online Plan Findr" tool steers patients into private plans that cover their specific regimen with minimal out-of-pocket cost, and MISTR pays up to $250/month of premium directly for as long as the patient remains active in care. The model is the same one MISTR pioneered for PrEP — where Emory University researchers found in a December 2025 JAMA paper that nearly one in five US PrEP recipients gets it through MISTR — extended to long-term HIV treatment.

For sex tech and sexual-health investors watching the telehealth-meets-public-health intersection, the announcement is a small but instructive signal. State-level retrenchment in safety-net HIV programs (Florida is the largest example so far in 2026, but Texas and Louisiana are facing similar pressure) creates exactly the gap that vertically integrated digital health players can monetize while doing real public-health work — a posture Hims & Hers, Ro, and Eddie/Giddy have not yet replicated for HIV-specific care. MISTR, owned by privately held Hims-and-Hers competitor Mistr Inc., is the only national-scale operator built specifically for the segment.

Sources

Update — 2026-04-27

Initial entry — story first created.